Huvitz Co. Ltd (065510) - Net Assets

Latest as of September 2025: ₩121.35 Billion KRW ≈ $82.24 Million USD

Based on the latest financial reports, Huvitz Co. Ltd (065510) has net assets worth ₩121.35 Billion KRW (≈ $82.24 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩235.07 Billion ≈ $159.30 Million USD) and total liabilities (₩113.72 Billion ≈ $77.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 065510 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩121.35 Billion
% of Total Assets 51.62%
Annual Growth Rate 6.82%
5-Year Change 55.18%
10-Year Change 76.87%
Growth Volatility 8.74

Huvitz Co. Ltd - Net Assets Trend (2011–2024)

This chart illustrates how Huvitz Co. Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Huvitz Co. Ltd (065510) market capitalisation.

Annual Net Assets for Huvitz Co. Ltd (2011–2024)

The table below shows the annual net assets of Huvitz Co. Ltd from 2011 to 2024. Also explore 065510 net assets growth trend to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2024-12-31 ₩121.79 Billion
≈ $82.53 Million
+10.14%
2023-12-31 ₩110.57 Billion
≈ $74.93 Million
+7.34%
2022-12-31 ₩103.01 Billion
≈ $69.81 Million
+17.11%
2021-12-31 ₩87.96 Billion
≈ $59.61 Million
+12.07%
2020-12-31 ₩78.48 Billion
≈ $53.19 Million
-10.79%
2019-12-31 ₩87.97 Billion
≈ $59.62 Million
+4.85%
2018-12-31 ₩83.90 Billion
≈ $56.86 Million
+6.64%
2017-12-31 ₩78.68 Billion
≈ $53.32 Million
+1.86%
2016-12-31 ₩77.25 Billion
≈ $52.35 Million
+12.19%
2015-12-31 ₩68.86 Billion
≈ $46.66 Million
+5.72%
2014-12-31 ₩65.13 Billion
≈ $44.14 Million
-0.26%
2013-12-31 ₩65.30 Billion
≈ $44.25 Million
-0.02%
2012-12-31 ₩65.32 Billion
≈ $44.26 Million
+26.40%
2011-12-31 ₩51.68 Billion
≈ $35.02 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Huvitz Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 44392.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩101.43 Billion 87.77%
Common Stock ₩6.08 Billion 5.26%
Other Components ₩8.06 Billion 6.97%
Total Equity ₩115.57 Billion 100.00%

Huvitz Co. Ltd Competitors by Market Cap

The table below lists competitors of Huvitz Co. Ltd ranked by their market capitalization.

Company Market Cap
PEDEVCO Corp
NYSE MKT:PED
$49.12 Million
Dong-A Hwa Sung Co.Ltd
KQ:041930
$49.18 Million
Tritax Big Box REIT plc
LSE:BBOX
$49.18 Million
Elliptic Laboratories AS
OL:ELABS
$49.19 Million
NEORIGIN Co. Ltd
KQ:094860
$49.09 Million
Deswell Industries Inc
NASDAQ:DSWL
$49.09 Million
Shareholder Value Beteiligungen AG
XETRA:SVE
$49.08 Million
Daelim B&Co
KO:005750
$49.08 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Huvitz Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 110,571,048,620 to 115,567,337,070, a change of 4,996,288,450 (4.5%).
  • Net income of 8,709,608,030 contributed positively to equity growth.
  • Dividend payments of 2,170,979,000 reduced retained earnings.
  • Share repurchases of 194,437,000 reduced equity.
  • New share issuances of 194,437,000 increased equity.
  • Other factors decreased equity by 1,542,340,580.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩8.71 Billion +7.54%
Dividends Paid ₩2.17 Billion -1.88%
Share Repurchases ₩194.44 Million -0.17%
Share Issuances ₩194.44 Million +0.17%
Other Changes ₩-1.54 Billion -1.33%
Total Change ₩- 4.52%

Book Value vs Market Value Analysis

This analysis compares Huvitz Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.63x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.00x to 0.63x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩6664.40 ₩6660.00 x
2017-12-31 ₩6787.26 ₩6660.00 x
2018-12-31 ₩7237.08 ₩6660.00 x
2019-12-31 ₩7723.44 ₩6660.00 x
2020-12-31 ₩7402.98 ₩6660.00 x
2021-12-31 ₩8296.65 ₩6660.00 x
2022-12-31 ₩9709.39 ₩6660.00 x
2023-12-31 ₩10186.28 ₩6660.00 x
2024-12-31 ₩10624.05 ₩6660.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Huvitz Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 7.54%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.39%
  • • Asset Turnover: 0.53x
  • • Equity Multiplier: 1.92x
  • Recent ROE (7.54%) is below the historical average (9.47%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 17.98% 15.38% 0.84x 1.40x ₩3.89 Billion
2012 17.87% 16.42% 0.80x 1.36x ₩4.87 Billion
2014 2.27% 2.16% 0.60x 1.76x ₩-4.69 Billion
2015 9.49% 9.38% 0.61x 1.66x ₩-354.18 Million
2016 14.33% 16.54% 0.48x 1.81x ₩3.34 Billion
2017 3.95% 4.42% 0.50x 1.79x ₩-4.76 Billion
2018 8.45% 8.99% 0.56x 1.69x ₩-1.30 Billion
2019 8.95% 8.95% 0.58x 1.73x ₩-923.08 Million
2020 -3.47% -3.89% 0.45x 1.98x ₩-10.57 Billion
2021 10.22% 9.46% 0.62x 1.74x ₩194.87 Million
2022 16.58% 15.60% 0.62x 1.72x ₩6.77 Billion
2023 9.02% 8.47% 0.59x 1.82x ₩-1.08 Billion
2024 7.54% 7.39% 0.53x 1.92x ₩-2.85 Billion

Industry Comparison

This section compares Huvitz Co. Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $369,574,017,331
  • Average return on equity (ROE) among peers: -8.34%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Huvitz Co. Ltd (065510) ₩121.35 Billion 17.98% 0.94x $49.10 Million
Shinhung (004080) $86.37 Billion 3.67% 0.52x $89.01 Million
HansBiomed Corporation (042520) $65.30 Billion 6.15% 0.41x $159.83 Million
JVM Co. Ltd (054950) $179.49 Billion 14.62% 0.43x $180.31 Million
U&I Corporation (056090) $57.68 Billion -32.14% 1.45x $83.27 Million
Vieworks Co. Ltd (100120) $188.04 Billion 17.80% 0.28x $151.39 Million
Corentec Co Ltd (104540) $24.09 Billion -123.57% 1.67x $34.83 Million
SD Biosensor Inc (137310) $2.34 Trillion -21.91% 0.39x $499.36 Million
Hironic Co. Ltd (149980) $41.60 Billion 7.64% 0.08x $48.82 Million
Humasis Co. Ltd (205470) $346.73 Billion 52.67% 0.35x $217.40 Million

About Huvitz Co. Ltd

KQ:065510 Korea Medical Devices
Market Cap
$49.10 Million
₩72.45 Billion KRW
Market Cap Rank
#22045 Global
#1353 in Korea
Share Price
₩6660.00
Change (1 day)
+0.30%
52-Week Range
₩6410.00 - ₩9830.00
All Time High
₩24879.57
About

Huvitz Co., Ltd. develops and sells optometric medical equipment worldwide. The company offers ophthalmic and optical equipment comprising refractive equipment, such as auto ref-keratometers, auto lensmeters, digital refractors, chart projectors, and unit tables; and diagnostic equipment comprising slit lamps, non-contact tonometers, and applanation tonometers, as well as ophthalmologic diagnosti… Read more